Log in

Vital Therapies Stock Price, Forecast & Analysis (NASDAQ:VTL)

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range N/A
50-Day Range
$0.83
MA: $8.88
$14.50
52-Week Range N/A
VolumeN/A
Average Volume21.62 million shs
Market Capitalization$35.17 million
P/E RatioN/A
Dividend YieldN/A
Beta3.51
Vital Therapies, Inc, a biotherapeutic company, focuses on developing cell-based therapies for the treatment of acute forms of liver failure. The company was formerly known as Vitagen Acquisition Corp. and changed its name to Vital Therapies, Inc in June 2003. Vital Therapies, Inc was founded in 2003 and is based in San Diego, California.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VTL
CUSIPN/A
Phone858-673-6840

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.29 per share

Profitability

Net Income$-41,470,000.00

Miscellaneous

Employees10
Market Cap$35.17 million
Next Earnings DateN/A
OptionableOptionable

Receive VTL News and Ratings via Email

Sign-up to receive the latest news and ratings for VTL and its competitors with MarketBeat's FREE daily newsletter.


Vital Therapies (NASDAQ:VTL) Frequently Asked Questions

What is Vital Therapies' stock symbol?

Vital Therapies trades on the NASDAQ under the ticker symbol "VTL."

How were Vital Therapies' earnings last quarter?

Vital Therapies (NASDAQ:VTL) announced its earnings results on Tuesday, August, 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.33) by $0.03. View Vital Therapies' Earnings History.

Has Vital Therapies been receiving favorable news coverage?

News stories about VTL stock have trended positive recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Vital Therapies earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Vital Therapies.

Who are some of Vital Therapies' key competitors?

What other stocks do shareholders of Vital Therapies own?

Who are Vital Therapies' key executives?

Vital Therapies' management team includes the folowing people:
  • Dr. Duane D. Nash M.B.A., M.D., J.D., M.B.A, CEO, Pres & Director (Age 48)
  • Mr. Robert A. Ashley, Exec. VP & Chief Scientific Officer (Age 61)
  • Mr. Michael V. Swanson M.B.A., M.B.A, Exec. VP, CFO & Treasurer (Age 64)
  • Mr. John M. Dunn, Gen. Counsel & Sec. (Age 67)

How big of a company is Vital Therapies?

Vital Therapies has a market capitalization of $0.00. Vital Therapies employs 10 workers across the globe.View Additional Information About Vital Therapies.

What is Vital Therapies' official website?

The official website for Vital Therapies is http://vitaltherapies.com/.

How can I contact Vital Therapies?

Vital Therapies' mailing address is 15222-B AVENUE OF SCIENCE, SAN DIEGO CA, 92128. The company can be reached via phone at 858-673-6840 or via email at [email protected]


MarketBeat Community Rating for Vital Therapies (NASDAQ VTL)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  332 (Vote Outperform)
Underperform Votes:  238 (Vote Underperform)
Total Votes:  570
MarketBeat's community ratings are surveys of what our community members think about Vital Therapies and other stocks. Vote "Outperform" if you believe VTL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VTL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/21/2019 by MarketBeat.com Staff

Featured Article: Trading Penny Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel